Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports

Hepatology

Volumn 63, Issue 2, 2016, Pages 590-603

  Björnsson, Einar S ^a,b   Hoofnagle, Jay H ^c,d  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPHETAMINE DERIVATIVE; ANABOLIC AGENT; ANDROGEN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; BUPRENORPHINE; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CORTICOSTEROID; ESTROGEN; FLUCLOXACILLIN; GASTROINTESTINAL AGENT; GESTAGEN; GOLD; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; IMMUNOMODULATING AGENT; MEPREDNISONE; MESALAZINE; NICOTINIC ACID; NIMESULIDE; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; RETINOL; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TETRACYCLINE; UNINDEXED DRUG; URINARY TRACT AGENT; DRUG;

ARTICLE; CLINICAL ASSESSMENT; DRUG CLASSIFICATION; DRUG FATALITY; HUMAN; LIVER INJURY; LIVER TOXICITY; PRIORITY JOURNAL; CLASSIFICATION; DRUG-INDUCED LIVER INJURY; MEDICAL RECORD;

DRUG-INDUCED LIVER INJURY; HUMANS; MEDICAL RECORDS; PHARMACEUTICAL PREPARATIONS;

EID: 84956829044     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28323     Document Type: Article

References (27)

1. Physician Desk Reference. http://www.pdr.net. Accessed May 1, 2015.
2. European Medicines Agency. www.ema.europa.eu. Accessed May 1, 2015.
3. Electronic Medicines Compendium. www.medicines.org.uk. Accessed May 1, 2015.
4. The Swedish Association of the Pharmaceutical Industry. FASS: the Swedish medicines information engine. http://service.lif.se/default.aspx?id=31983. Accessed May 1, 2015.
5. Bjornsson ES, Jacobsen EI, Einarsdottir R, Chalasani N. Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications. Gastroenterology 2015;148:269-273.
6. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. http://livertox.nih.gov. Accessed May 1, 2015.
7. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
8. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336.
9. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-455.
10. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al.; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521.
11. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and gender. Hepatology 2009;49:2001-2009.
12. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-489.
13. Björnsson B, Bergqvist A, Jerlstad P, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005;40:1095-1101.
14. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006;24:1187-1195.
15. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of iceland. Gastroenterology 2013;144:1419-1425.
16. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al.; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-1934.
17. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 889 patients with drug-induced liver injury: the DILIN Prospective Study. Gastroenterology 2015;48:1340-1352.
18. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010;105:2396-2404.
19. Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. Ann Hepatol 2014;13:231-239.
20. Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf 2014;37(Suppl. 1):S9-S17.
21. Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 2009;54:84-90.
22. Andrade RJ, Robles M, Lucena MI. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf 2009;8:709-714.
23. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:425-456.
24. Pavel S, Burty C, Alcaraz I, de la Tribonnière X, Baclet V, Ajana F, et al. Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS 2007;21:268-269.
25. Bräu N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three AIDS patients treated with indinavir. Lancet 1997;349:924-925.
26. Vergis E, Paterson DL, Singh N. Indinavir-associated hepatitis in patients with advanced HIV infection. Int J STD AIDS 1998;9:53.
27. García-Cortés M, Stephens C, Lucena MI, Fernández-Castañer A, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011;55:683-691.